Details of the Drug

General Information of Drug (ID: DMNPZL4)

Drug Name

Dacarbazine

Synonyms

Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

182.18

Topological Polar Surface Area (xlogp)

-0.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is unstablely, slowly and incompletely absorbed [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.6 mL/min/kg [4]
Elimination: 39% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 hours [4]
Metabolism: The drug is metabolized via the hepatic [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.7 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 1% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 4.2 mg/mL [3]

Chemical Identifiers

Formula: C6H10N6O
IUPAC Name: 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
Canonical SMILES: CN(C)/N=N/C1=C(NC=N1)C(=O)N
InChI: InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N

Cross-matching ID

PubChem CID: 135398738
ChEBI ID: CHEBI:94587
CAS Number: 4342-03-4
DrugBank ID: DB00851
TTD ID: D0Y7ZU
INTEDE ID: DR0404
ACDINA ID: D00979

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[7]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dacarbazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[48]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[49]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Roflumilast.	Asthma [CA23]	[50]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[51]
ABT-492	DMJFD2I	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[51]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[51]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[52]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Cannabidiol.	Epileptic encephalopathy [8A62]	[50]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[53]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[54]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[55]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Denosumab.	Low bone mass disorder [FB83]	[56]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[57]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Idelalisib.	Mature B-cell leukaemia [2A82]	[58]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Dacarbazine and Thalidomide.	Multiple myeloma [2A83]	[59]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Tecfidera.	Multiple sclerosis [8A40]	[60]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Siponimod.	Multiple sclerosis [8A40]	[48]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Fingolimod.	Multiple sclerosis [8A40]	[61]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Ocrelizumab.	Multiple sclerosis [8A40]	[62]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Ozanimod.	Multiple sclerosis [8A40]	[50]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[63]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[51]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Canakinumab.	Rheumatoid arthritis [FA20]	[64]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Rilonacept.	Rheumatoid arthritis [FA20]	[64]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Golimumab.	Rheumatoid arthritis [FA20]	[65]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Dacarbazine and Leflunomide.	Rheumatoid arthritis [FA20]	[66]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Dacarbazine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[67]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Azathioprine.	Transplant rejection [NE84]	[48]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Ganciclovir.	Virus infection [1A24-1D9Z]	[48]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Valganciclovir.	Virus infection [1A24-1D9Z]	[48]
-----------


⏷ Show the Full List of 35 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dacarbazine 200mg/vial injectable	200mg/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
7	Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
8	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
9	Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71.
10	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
11	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
12	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
13	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
14	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
15	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
18	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
19	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
20	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
21	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
22	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
23	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
24	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
25	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
26	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
27	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
28	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
29	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
30	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
31	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
32	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
33	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
34	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
36	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
37	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
38	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
39	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
40	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
41	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
42	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
43	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
44	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
45	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
46	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
47	Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
48	Cerner Multum, Inc. "Australian Product Information.".
49	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
50	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
52	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
53	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
54	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
55	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
56	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
57	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
58	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
59	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
60	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
61	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
62	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
63	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
64	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
65	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
66	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
67	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]